Hydrogen sulfide regulation of renal and mesenteric blood flow

• Published in: American journal of physiology. Heart and circulatory physiology 2019-11, Vol.317 (5), p.H1157-H1165
• Main Authors: Morales-Loredo, Humberto, Barrera, Adelaeda, Garcia, Joshua M, Pace, Carolyn E, Naik, Jay S, Gonzalez Bosc, Laura V, Kanagy, Nancy L
• Format: Article
• Language: English
• Subjects: Alanine - analogs & derivatives; Alanine - pharmacology; Animals; Arterial Pressure; Blood Flow Velocity; Cystathionine gamma-Lyase - antagonists & inhibitors; Cystathionine gamma-Lyase - metabolism; Enzyme Inhibitors - pharmacology; Hydrogen Sulfide - metabolism; Male; Mesenteric Arteries - drug effects; Mesenteric Arteries - metabolism; Rats, Sprague-Dawley; Renal Artery - drug effects; Renal Artery - metabolism; Renal Circulation - drug effects; Splanchnic Circulation - drug effects; Sulfides - pharmacology; Vascular Resistance
• ISSN: 0363-6135; 1522-1539
• DOI: 10.1152/ajpheart.00303.2019

Hydrogen sulfide (H S) dilates isolated arteries, and knockout of the H S-synthesizing enzyme cystathionine γ-lyase (CSE) increases blood pressure. However, the contributions of endogenously produced H S to blood flow regulation in specific vascular beds are unknown. Published studies in isolated arteries show that CSE production of H S influences vascular tone more in small mesenteric arteries than in renal arteries or the aorta. Therefore, the goal of this study was to evaluate H S regulation of blood pressure, vascular resistance, and regional blood flows using chronically instrumented rats. We hypothesized that during whole animal CSE inhibition, vascular resistance would increase more in the mesenteric than the renal circulation. Under anesthesia, CSE inhibition [β-cyanoalanine (BCA), 30 mg/kg bolus + 5 mg·kg ·min for 20 min iv) rapidly increased mean arterial pressure (MAP) more than saline administration (%Δ: saline -1.4 ± 0.75 vs. BCA 7.1 ± 1.69, < 0.05) but did not change resistance (MAP/flow) in either the mesenteric or renal circulation. In conscious rats, BCA infusion similarly increased MAP (%Δ: saline -0.8 ± 1.18 vs. BCA 8.2 ± 2.6, < 0.05, = 7) and significantly increased mesenteric resistance (saline 0.9 ± 3.1 vs. BCA 15.6 ± 6.5, < 0.05, = 12). The H S donor Na S (50 mg/kg) decreased blood pressure and mesenteric resistance ,but the fall in resistance was not significant. Inhibiting CSE for multiple days with dl-proparglycine (PAG, 50 mg·kg ·min iv bolus for 5 days) significantly increased vascular resistance in both mesenteric (ratio of : saline 0.86 ± 0.033 vs. PAG 1.79 ± 0.38) and renal circulations (ratio of : saline 1.26 ± 0.22 vs. 1.98 ± 0.14 PAG). These results support our hypothesis that CSE-derived H S is an important regulator of blood pressure and vascular resistance in both mesenteric and renal circulations. Furthermore, inhalation anesthesia diminishes the effect of CSE inhibition on vascular tone. These results suggest that CSE-derived H S has a prominent role in regulating blood pressure and blood flow under physiological conditions, which may have been underestimated in prior studies in anesthetized subjects. Therefore, enhancing substrate availability or enzyme activity or dosing with H S donors could be a novel therapeutic approach to treat cardiovascular diseases.